Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Wall Street Futures Slip as Tech Stocks Struggle Ahead of Key US Economic Data 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
